CAS: 50492-22-3; 4-Perhydroazepinone Hydrochloride

相似化合物

188975-88-4 83621-33-4 1208-75-9

上下游产品

CAS号623-73-4 重氮乙酸乙酯 | CAS号29976-53-2 N-乙氧羰基-4-哌啶酮 | CAS号141642-82-2 1-B°C-5-氧代氮杂环庚烷... | CAS号19786-58-4 5-氧代氮杂烷-1,4-二羧酸二乙酯 | CAS号1208-75-9 1-苄基六氢氮杂卓-4-酮 | CAS号188975-88-4 4-氧代氮杂环庚烷-1-羧酸叔丁酯 | CAS号74134-07-9 N-苯基氮杂环庚烷-4-胺 | CAS号50492-23-4 1-乙酰基六氢-4H-氮杂-4-酮 | CAS号56515-89-0 1-Carbethoxyaze...

4-氧代氮杂环庚烷-1-羧酸叔丁酯置于盐酸体系中,用 1,4-二氧六环 作为反应溶剂,化学反应 16.0H,以71%的收率获得产物4-氮杂卓酮盐酸盐
参考文献: Phosphonates As Inhibitors Of Enpp1 And Cdnp[fr] Phosphonates En Tant Qu'Inhibiteurs D'Enpp1 Et Cdnp
标题: Phosphonates As Inhibitors Of Enpp1 And Cdnp[fr] Phosphonates En Tant Qu'Inhibiteurs D'Enpp1 Et Cdnp
摘要:本文提供具有enpp1,Cdnp或两者抑制剂活性的化合物.其中一些实施例提供具有以下结构之一的化合物(I)或(II),或其药学上可接受的盐,互变异构体,立体异构体或前药,其中r1,R2,R3,R4,R5,R6,R7A,R7B,R7B,R7C,R25,R26,R27A,R27B,R27C,L1,L5,L6,G1,G2,G3和g6如本文所定义.本文提供了与制备和使用此类化合物相关的方法,包含此类化合物的药物组合物以及用于治疗与enpp1相关的疾病的方法,包括哺乳动物中的未受控制的细胞增殖,癌症和病毒或细菌感染.

专利信息

专利号:US-8772301-B2
优先权日:2009-12-18
标题 :Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
发明人：HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D
权利人:HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

专利号:US-8575148-B2
优先权日:2008-12-12
标 题:Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
发明人：SMID PIETER; MLINARIC MICHAEL; KOEHLER KONRAD F; NUNEZ GARCIA SARA; WEGENER ELMAR; LANGE JOSEPHUS H M
权利人:SMID PIETER; MLINARIC MICHAEL; KOEHLER KONRAD F; NUNEZ GARCIA SARA; WEGENER ELMAR; LANGE JOSEPHUS H M; ABBOTT HEALTHCARE PRODUCTS BV
摘要:This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): n nwherein R 1 , R 2 , (R 3 ) n , and (R 4 ) m have the meanings given in the specification.

专利号:CN-114507184-B
优先权日:2020-11-17
标题:Synthesis method and application of 1-methylhexahydroazepine-4-one hydrochloride